IND SWIFT LABORATORIES LT
Latest filings
Next results: Thu, 29 Oct · Financial Results- Board meeting on Oct 29, 2026 to consider Q2 FY26 results · Results
- Promoter group acquires 14 lakh shares via warrant conversion at Ind-Swift Labs · Ownership Changes
- Promoter Essix Biosciences converts 14 lakh warrants into equity shares · Ownership Changes
Snapshot
What the business is, and whether it's a good one at a fair price.
Manufactures pharmaceutical products, with FY26 revenue of Rs 641.29 crore. Operations are centred at a manufacturing site in Derabassi, Punjab, where a centralised warehouse with 11,000-pallet capacity is being built under an MOU worth about Rs 40 crore, adjoining the existing Global Business Unit. Overseas reach is supported through a Dubai subsidiary, identified as a recipient of fresh investment. The cost structure is materials-heavy, with raw materials at 42.4% of revenue and employees at 21.5%; other operating expenses add 27.4% and depreciation 4.8%. A Rs 137.20 crore preferential warrant issue to a promoter group entity is being put to shareholders, with Rs 53 crore earmarked for working capital, Rs 41.40 crore for further manufacturing and warehouse expansion, Rs 5 crore for the Dubai subsidiary, Rs 2 crore for R&D and Rs 1.5 crore for a technology upgrade. An earlier Rs 255.61 crore preferential warrant issue was deployed across business expansion, subsidiary investments, working capital and general corporate purposes.
Scorecard
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
Strengths
Concerns
Charts
How has the market priced it — with filings on the timeline?
INDSWFTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Peers
How does it stack up on valuation, returns and growth?
Loading peers…
Financials
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Ownership
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Common questions
Answered from IND SWIFT LABORATORIES LT's filed financials and exchange disclosures
What does IND SWIFT LABORATORIES LT do?
IND SWIFT LABORATORIES LT is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol INDSWFTLAB.
Is IND SWIFT LABORATORIES LT profitable?
Yes. Over the trailing twelve months IND SWIFT LABORATORIES LT reported a net profit of ₹57 Cr on revenue of ₹665 Cr.
Does IND SWIFT LABORATORIES LT pay a dividend?
Not in the latest reported year — IND SWIFT LABORATORIES LT's dividend payout for FY26 was nil.
Is IND SWIFT LABORATORIES LT debt-free?
On a net basis, yes. It reported borrowings of ₹18 Cr on its 31 Mar 2026 balance sheet, but holds ₹412 Cr more cash than debt.
Is IND SWIFT LABORATORIES LT expensive compared with its peers?
On trailing P/E, IND SWIFT LABORATORIES LT ranks 121 of 158 in Pharmaceuticals — cheaper than 24% of them, against an industry median of 30.8×. This is a position, not a valuation judgement.
How much does the IND SWIFT LABORATORIES LT share price move in a day?
On a typical session IND SWIFT LABORATORIES LT moves 1.86% — that is the median absolute close-to-close move across its last 267 trading days. MarketPing measures each filing's price reaction against it.
When are IND SWIFT LABORATORIES LT's next results?
Financial Results on Thu, 29 Oct. MarketPing alerts you on WhatsApp the moment the filing lands.
Where can I track IND SWIFT LABORATORIES LT's announcements?
Every NSE and BSE filing by IND SWIFT LABORATORIES LT appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.